Norra Vallgatan 72
Malmö 211 22
Sweden
46 7 39 03 69 69
https://pilapharma.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 1
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Ms. Dorte Xenia Gram | Founder, Chairman & Chief Scientific Officer | 1,99M | N/A | 1969 |
Ms. Elna Lembrer Astrom | Chief Financial Officer | 497,31k | N/A | 1961 |
Mr. Gustav Hanghoj Gram | Chief Executive Officer | N/A | N/A | N/A |
Mr. Miguel Lecumberri | Head of Compliance & Legal Affairs | N/A | N/A | N/A |
Mr. Masoud Alavi | Head of Corporate Visual Communication | N/A | N/A | N/A |
Mr. Andy Makin | Head of Toxicology | N/A | N/A | N/A |
Ms. Maura McArdle | Head of BD & Quay Pharma | N/A | N/A | N/A |
Mr. Mike Frodsham | CTO of Quay Pharma | N/A | N/A | N/A |
Ms. Alison Foster | Head of Pre-Clinical - Quay Pharma | N/A | N/A | N/A |
Mr. Simon Hamilton | Head of Global Business Development - Almac | N/A | N/A | N/A |
PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2b clinical trials for type 2 diabetes. The company was incorporated in 2014 and is based in Malmö, Sweden.
Pila Pharma AB (publ)s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.